Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx (NYSE: VNRX) reported its full fiscal year 2024 results, achieving $1.2 million in revenue, a 59% increase from the previous year. The company's Nu.Q® Vet revenue grew 75% while Nu.Q® Discover revenue increased 40% compared to 2023.
Key operational highlights include the sale of approximately 120,000 Nu.Q® Vet Cancer Tests in 2024 and expansion to over 20 countries. Operating expenses decreased by 23% year-over-year, with second-half expenses down 31%. The company ended 2024 with $3.3 million in cash and subsequently received $1.8 million in non-dilutive funding from Belgian institutions and raised $2.3 million through a registered direct offering.
The company is advancing commercial discussions with major players in human diagnostics and liquid biopsy for sepsis and oncology markets, aiming to secure multiple licensing deals in 2025. Volition targets cash neutrality in 2025, expecting income, including licensing receipts, to match expenditure.
VolitionRx (NYSE AMERICAN: VNRX) announces two significant poster presentations at ESMO's European Lung Cancer Congress (ELCC) 2025 in Paris. The presentations focus on the company's innovative biomarker technologies:
1. The Nu.Q® H3K27Me3 biomarker, combined with circulating tumor DNA, shows potential to improve prognostic value for overall survival and treatment decision-making in Non Small Cell Lung Cancer (NSCLC).
2. The Nu.Q® H3.1 low-cost immunoassay demonstrates potential for early identification of high-risk cancer subjects.
The presentations, scheduled for March 28, 2025, include studies on early detection of stage I/II NSCLC and H3K27Me3-nucleosome as a prognostic biomarker in NSCLC, with analysis of up to 832 patients at baseline.
VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 AM ET, focusing on their Nu.Q® Cancer platform. Key executives including Chief Commercial Officer Gael Forterre, Chief Medical Officer Dr. Andrew Retter, and Chief Scientific Officer Dr. Jake Micallef will present.
The event will showcase findings from large independent studies supporting their Nu.Q® platform in cancer detection. Notably, recent research undergoing peer review indicates that the Nu.Q® Cancer test successfully detected multiple common cancers (lung, breast, prostate, colon, and liver) with an overall AUC of 86% and low false positive rates.
The company is targeting two significant market opportunities:
- The lung cancer market (screening, prognostication, and minimal residual disease) estimated at $4 billion
- The liquid biopsy market for multi-cancer early detection in the U.S., valued at approximately $20 billion
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering to raise up to $2.3 million through the sale of common stock. The offering includes:
- 2,363,636 shares at $0.55 per share to company insiders (directors, executive officers, and existing stockholders)
- 1,739,087 shares at $0.55 per share with accompanying warrants to other existing stockholders and new investors
The warrants allow purchase of up to 1,739,087 additional shares at $0.66 per share, exercisable immediately and expiring in five years, potentially generating an additional $1.1 million if fully exercised. The offering, expected to close around March 26, 2025, will be conducted directly without a placement agent. Funds will support research, product development, clinical studies, commercialization, and working capital.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Full Fiscal Year 2024 Earnings Conference Call and Business Update for Monday, March 31, 2025, at 4:30 p.m. U.S. Eastern Time. The conference call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), Terig Hughes (Group CFO), and Dr. Andrew Retter (Chief Medical Officer).
The call will cover Q4 and full fiscal year 2024 financial results, operating performance, and provide updates on important events from 2024 and upcoming milestones. Investors can access the call through various dial-in numbers: U.S. & Canada (1-877-407-9716, toll-free), U.K. (0 800 756 3429, toll-free), and International (1-201-493-6779). A replay will be available until April 14, 2025.
VolitionRx (NYSE: VNRX) has announced promising results from a study of its automated Nu.Q® Cancer immunoassay test, demonstrating the test's ability to detect 21 different types of cancer. The test, which features a low false positive rate among healthy individuals, can be utilized either as a standalone pan-cancer screening tool or in combination with other liquid biopsy technologies to enhance accuracy.
The company is actively pursuing licensing agreements with major diagnostic and liquid biopsy companies, targeting multiple partnerships with milestone payments and ongoing revenue streams in 2025. A key advantage of Volition's nucleosome assays is their compatibility with existing automated chemiluminescence platforms worldwide, eliminating the need for new hardware investment. The technology targets the $20 billion Total Annual Accessible Market for liquid biopsy multi-cancer early detection in the U.S.
VolitionRx (NYSE AMERICAN: VNRX) has released a new lung cancer primer titled 'Lung Cancer: Hope of a Brighter Tomorrow,' showcasing their Nu.Q® Cancer blood test technology. The report highlights the potential of Nu.Q® Cancer assays in revolutionizing lung cancer diagnosis, treatment, and monitoring in the $4 billion lung cancer market.
The technology offers easy-to-administer, low-cost blood tests that can be integrated with existing methods like Low Dose Computed Tomography and Next Generation Sequencing (NGS). A notable 1050-patient retrospective study on Non-Small Cell Lung Cancer associated with NGS will be presented at the upcoming European Lung Cancer Congress in Paris.
The company is currently in discussions with major diagnostics and liquid biopsy companies, aiming to secure multiple licensing agreements this year. Nu.Q® Cancer tests can be run on existing automated chemiluminescence platforms worldwide, making them potentially widely accessible through licensing and partnership arrangements.
VolitionRx (NYSE AMERICAN: VNRX) announced its silver sponsorship of the 44th Annual ISICEM Congress in Brussels, Belgium, from March 18-21, 2025. The company will support multiple presentations highlighting their Nu.Q® H3.1 epigenetic screening technology in intensive care and emergency medicine settings.
The congress will feature six presentations focusing on various aspects of NETosis, NETs, and nucleosomes-H3.1 in sepsis screening and monitoring. Dr. Andrew Retter, Volition's Chief Medical Officer, emphasized the significance of these studies in validating their technology's role in sepsis care, noting a potential $1B+ market opportunity in this sector.
Additionally, Dr. Retter will speak at the Praetorian Doctoral Network Satellite Symposium on March 19th, discussing the Nu.Q® test for measuring circulating H3.1 nucleosomes as markers for neutrophil extracellular traps in blood.
VolitionRx (NYSE AMERICAN: VNRX) has expanded its Nu.Q® Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan. The new five-year agreement includes Volition's chemiluminescent immunoassay (ChLIA) version via the IDS i10® automated analyzer platform.
The expansion builds upon the previous agreement that offered the manual ELISA format test. Fujifilm Vet Systems plans to launch the automated platform for canine cancer screening in summer 2025, following final validation and verification. Since the initial launch in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test.
The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test through its network of central reference laboratories in Japan, targeting a market of approximately seven million pet dogs.
VolitionRx (NYSE AMERICAN: VNRX) has announced the enrollment of its first patient in a clinical validation study for its Nu.Q® Cancer technology at National Taiwan University Hospital. The study aims to evaluate the technology's ability to differentiate between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer.
The 500-patient prospective validation study follows promising results from a previous study published on March 7th, 2025, which showed Nu.Q® Cancer's high sensitivity in identifying malignant nodules. The current study is expected to be completed by the end of 2025.
If successful, the Nu.Q® test could be integrated into national lung cancer screening programs, potentially reducing false positives and unnecessary invasive procedures. The blood-based test aims to support physicians in clinical decision-making by identifying high-risk patients and those who might avoid unnecessary biopsies.
